Logo
x

Search

Subscribe Now

Melanoma

Merck Presents New Data of Keytruda (pembrolizumab) in Three Studies for the Treatment of Melanoma at SMR 2021

Merck Presents New Data of Keytruda (pembrolizumab) in Three Studies for the Treatment of Melanoma at SMR 2021

  • November 1, 2021
IO Biotech's IO102 + IO103 Receive the US FDA's Breakthrough Therapy Designation for Unresectable/ Metastatic Melanoma

IO Biotech's IO102 + IO103 Receive the US FDA's Breakthrough Therapy Designation for Unresectable/ Metastatic Melanoma

  • December 15, 2020
Novartis Reports Results of Dual regimen in P-III COMBI-AD Study for Patients with Stage III Melanoma

Novartis Reports Results of Dual regimen in P-III COMBI-AD Study for Patients with Stage III Melanoma

  • September 17, 2020
Regeneron Collaborates with BioNTech to Advance the Combination of FixVac and Libtayo (cemiplimab) in Melanoma

Regeneron Collaborates with BioNTech to Advance the Combination of FixVac and Libtayo (cemiplimab) in Melanoma

  • August 3, 2020
Henlius Receives NMPA's IND Approval for its HLX13 (biosimilar- ipilimumab)

Henlius Receives NMPA's IND Approval for its HLX13 (biosimilar- ipilimumab)

  • April 8, 2020
Merck's Keytruda (pembrolizumab) Receives FDA's Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node

Merck's Keytruda (pembrolizumab) Receives FDA's Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymp...

  • February 20, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.